Literature DB >> 21991956

Steady progress against HER2-positive breast cancer.

Daniel F Hayes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21991956     DOI: 10.1056/NEJMe1101326

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Design of clinical trials for biomarker research in oncology.

Authors:  Sumithra J Mandrekar; Daniel J Sargent
Journal:  Clin Investig (Lond)       Date:  2011-12

2.  A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors.

Authors:  Farah B Rahmatpanah; Zhenyu Jia; Xin Chen; Jessica E Char; Bozhao Men; Anna-Clara Franke; Frank E Jones; Michael McClelland; Dan Mercola
Journal:  Oncotarget       Date:  2015-01-20

3.  Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.

Authors:  Torsten O Nielsen; Samuel C Y Leung; David L Rimm; Andrew Dodson; Balazs Acs; Sunil Badve; Carsten Denkert; Matthew J Ellis; Susan Fineberg; Margaret Flowers; Hans H Kreipe; Anne-Vibeke Laenkholm; Hongchao Pan; Frédérique M Penault-Llorca; Mei-Yin Polley; Roberto Salgado; Ian E Smith; Tomoharu Sugie; John M S Bartlett; Lisa M McShane; Mitch Dowsett; Daniel F Hayes
Journal:  J Natl Cancer Inst       Date:  2021-07-01       Impact factor: 13.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.